Directorship Changes
The economic case for medicinal cannabis
In the last few years, it has become increasingly evident that medicinal cannabis is not only revolutionising the way we manage specific health issues, it’s also quietly transforming the economic
Celadon Pharmaceuticals (AIM:CEL) New Committed Credit Facility
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
Celadon Pharmaceuticals PLC (AIM:CEL) soared over 25% after finance update
Shares in Celadon Pharmaceuticals PLC (AIM: CEL), a UK-based pharmaceutical company specialising in cannabis-based medicines, surged over 25% in early trading following a financial update.
Celadon Pharmaceuticals (AIM:CEL) shares drop 50% due to funding delays
Shares in Celadon Pharmaceuticals PLC (AIM: CEL) plummeted 50% in early trading due to delays in accessing £1.3 million of funding.
Germany Legalizes Recreational Cannabis, Becoming the Largest EU Nation to Do So.
On Monday, Germany legalized recreational cannabis use, marking it the largest EU nation to do so, amidst strong opposition from some politicians and medical groups.
The value of the illegal cannabis market in the UK is currently estimated at approximately £2.6 billion.
The illegal cannabis market in Britain, estimated at £2.6 billion annually, poses a significant challenge for authorities amidst growing interest in its use for pain relief.
Germany becomes ninth country to authorize the recreational use of cannabis.
Today, Germany marked its entry as the ninth nation to authorize the recreational use of cannabis.
The legalization of cannabis in Germany could potentially inspire other European nations, including the UK, to follow in its footsteps.
After Germany’s cabinet greenlit new legislation permitting the recreational use and cultivation of cannabis, predictions have emerged that the rest of Europe, including the UK, may follow suit.
Ananda (AQSE:ANA) Developments Secures Funding for Endometriosis Clinical Trial
Ananda Developments Plc (AQSE: ANA), a developer of cannabinoid medicines, has secured the necessary funding to initiate a trial to test the effectiveness of its cannabidiol oil, MRX1, in treating
Ananda Developments (AQSE:ANA) First Cannabinoid Medicines Launched
Ananda’s ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
Company Profile (AQSE:ANA) Ananda Developments
Ananda Developments (AQSE: ANA) is an AQUIS-listed healthcare company involved in the development of cannabinoid-based medicines with two concurrently running, third-party funded, Phase II randomised control trials (RCTs).